Inotersen vs Patisiran

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Transthyretin Amyloidosis with Polyneuropathy

Shared mechanism: Transthyretin (TTR) · full Transthyretin Amyloidosis with Polyneuropathy pipeline

Inotersen · Tegsedi

Rights held by Ionis Pharmaceuticals and partners

US approval withdrawn in Transthyretin Amyloidosis with Polyneuropathyantisense
Reliable signal

NCT01737398 · Phase 2/3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial in 172 patients. Both co-primary endpoints, a validated neuropathy impairment score and a quality-of-life questionnaire, showed statistically significant benefit with inotersen versus placebo at week 66.

No aligned efficacy figure on record for this race.

Patisiran · ONPATTRO

Marketed by Alnylam Pharmaceuticals

Approved in Transthyretin Amyloidosis with PolyneuropathyRNAi
Reliable signal

NCT01960348 · Phase 3 · completed

In this randomized, double-blind, placebo-controlled phase 3 trial, 225 participants received patisiran (148) or placebo (77). The hard clinical primary endpoint, change in mNIS+7 at 18 months, favored patisiran and was statistically significant: -6.03 versus 27.96 points, a between-group difference of -33.99 (p<0.0000001).

Reported efficacy

Modified Neuropathy Impairment Score +7 (mNIS+7) (18mo): Modified Neuropathy Impairment Score +7 (mNIS+7) (18mo): Patisiran (ALN-TTR02) -6.03 score on a scale (Standard Error 1.739) | Placebo 27.96 score on a scale (Standard Error 2.602) (met)

Result source: NCT01960348

Results for Transthyretin Amyloidosis with Polyneuropathy

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Inotersen: registry results are on file for Transthyretin Amyloidosis with Polyneuropathy, but their comparison mappings are not yet available.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Patisiran
Modified Neuropathy Impairment Score +7 (mNIS+7) (18mo): Patisiran (ALN-TTR02) -6.03 score on a scale (Standard Error 1.739) | Placebo 27.96 score on a scale (Standard Error 2.602) NCT01960348 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Inotersen's landscape · Patisiran's landscape